Early Implant Stability Improved by Nutraceutical Support: Results from a Prospective Randomized Clinical Trial Based on Resonance Frequency Analysis

Background: Osseointegration is the cornerstone of long-term implant success, and systemic factors such as nutritional status may influence the biological cascade of peri-implant bone healing. Nutraceuticals have been proposed as adjuvant strategies to enhance bone metabolism, but clinical evidence remains scarce. This study aimed to evaluate the effect of a novel nutraceutical formulation (Osteo-therapy®, Laboratorio Farmaceutico ERFO S.p.A., Messina, Italy; composed of spirulina standardized with 40% phycocyanin, quercetin, vitamin D3, and calcium) on early implant stability. Methods: A prospective, randomized clinical trial (RCT) was conducted in accordance with CONSORT guidelines (PLATFORM Project OR12.1). Sixty healthy patients requiring mandibular implants were enrolled (test n = 30 with Osteo-therapy®; control n = 30). Stability was assessed via RFA (ISQ values) at baseline (T0), 1 month (T1), 2 months (T2), and 3 months (T3). Results: Both groups showed increases in ISQ. No significant differences were found at T0 and T1 (p = 0.149 and p = 0.737). From T2 onward, the test group exhibited significantly higher ISQ values (T2: 73.17 vs. 69.50, p < 0.001; T3: 78.37 vs. 76.63, p = 0.006). Conclusions: Osteo-therapy® significantly enhanced early implant stability, indicating an accelerated transition from primary to secondary stability, potentially supporting earlier loading protocols.